Interleukin-7
Sponsors
Cytheris SA, Revimmune, University Hospital, Limoges
Conditions
COVID-19HIVHepatitis CLymphocytopeniaSevere Sepsis With Septic Shock
Phase 1
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
CompletedNCT01025596
Start: 2007-05-31End: 2012-03-31Updated: 2012-10-18
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
NCT01025297
Start: 2008-07-31End: 2013-03-31Target: 18Updated: 2012-10-18
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
NCT01024894
Start: 2009-01-31End: 2012-12-31Target: 15Updated: 2012-10-18
Phase 2
Study on Interleukin-7 (CYT107) in HIV Patients
TerminatedNCT01190111
Start: 2010-01-31End: 2013-06-30Updated: 2013-08-01
A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
CompletedNCT02640807
Start: 2016-01-31End: 2018-08-27Updated: 2020-07-09
Immune Reconstitution of Immunosuppressed Sepsis Patients
TerminatedNCT02797431
Start: 2016-01-14End: 2017-11-13Updated: 2017-11-29
InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
TerminatedNCT04379076
Start: 2020-05-14End: 2022-03-30Updated: 2022-04-07
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
TerminatedNCT04407689
Start: 2020-06-08End: 2022-03-30Updated: 2022-04-08
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
TerminatedNCT04927169
Start: 2021-03-01End: 2022-03-30Updated: 2024-04-12